Vanguard Group Inc. Increases Stake in DexCom, Inc. $DXCM

Vanguard Group Inc. raised its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 1.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 48,322,405 shares of the medical device company’s stock after acquiring an additional 866,506 shares during the quarter. Vanguard Group Inc. owned approximately 12.32% of DexCom worth $4,218,063,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Dorsey & Whitney Trust CO LLC purchased a new position in DexCom during the second quarter valued at $280,000. Intrust Bank NA raised its stake in shares of DexCom by 24.7% in the second quarter. Intrust Bank NA now owns 4,934 shares of the medical device company’s stock worth $431,000 after buying an additional 976 shares during the period. Nomura Asset Management Co. Ltd. lifted its position in shares of DexCom by 2.9% during the 2nd quarter. Nomura Asset Management Co. Ltd. now owns 159,910 shares of the medical device company’s stock valued at $13,959,000 after buying an additional 4,568 shares in the last quarter. Rockefeller Capital Management L.P. bought a new position in shares of DexCom during the 2nd quarter valued at approximately $876,000. Finally, Ontario Teachers Pension Plan Board purchased a new stake in DexCom in the 2nd quarter worth approximately $922,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Oppenheimer downgraded shares of DexCom from an “outperform” rating to a “market perform” rating in a report on Monday, September 8th. Piper Sandler set a $75.00 target price on shares of DexCom and gave the company a “buy” rating in a research note on Friday, October 31st. Wells Fargo & Company set a $93.00 price target on DexCom and gave the stock an “overweight” rating in a research note on Friday, October 31st. Citigroup decreased their price target on DexCom from $85.00 to $75.00 and set a “buy” rating on the stock in a report on Friday, October 31st. Finally, The Goldman Sachs Group lowered their price objective on DexCom from $104.00 to $89.00 and set a “buy” rating on the stock in a research report on Wednesday, October 1st. Three analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $87.62.

DexCom Stock Performance

DXCM opened at $59.73 on Thursday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The stock has a market capitalization of $23.30 billion, a price-to-earnings ratio of 41.48, a PEG ratio of 1.43 and a beta of 1.40. The company has a fifty day moving average of $66.17 and a 200 day moving average of $76.90. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $93.25.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.57 by $0.04. The business had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business’s revenue was up 21.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.45 EPS. DexCom has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Activity at DexCom

In other news, Director Kyle Malady sold 667 shares of the company’s stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $80.86, for a total transaction of $53,933.62. Following the sale, the director directly owned 22,667 shares of the company’s stock, valued at $1,832,853.62. This represents a 2.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Sadie Stern sold 1,466 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $80.00, for a total value of $117,280.00. Following the transaction, the executive vice president owned 105,223 shares of the company’s stock, valued at $8,417,840. This represents a 1.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 9,999 shares of company stock valued at $619,391 in the last 90 days. 0.32% of the stock is currently owned by insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.